Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor α (ERα), Differentially Affect ERα Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells

Molecular Endocrinology

Volumn 17, Issue 10, 2003, Pages 2013-2027

  Marsaud, Véronique ^a   Gougelet, Angélique ^a   Maillard, Sébastien ^a   Renoir, Jack Michel ^a  

^a UNIV PARIS SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 HYDROXYTAMOXIFEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOHEXIMIDE; ENZYME ACTIVATOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEASOME; PROTEIN KINASE; PROTEIN KINASE C; PROTEIN P42; PROTEIN P44; SB 023580; SB 203190; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CELL COMPARTMENTALIZATION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DEGRADATION; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; EXTRACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; SOLUBILITY; TRANSCRIPTION INITIATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYSTEINE ENDOPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; LIGANDS; MAP KINASE KINASE KINASES; MULTIENZYME COMPLEXES; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSCRIPTION, GENETIC;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0142056952     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2002-0269     Document Type: Article

References (71)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesomo K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear hormone receptor superfamily: the second decade. Cell 83:835-839
2. Pratt WB, Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-360
3. Marsaud V, Radanyi C, Renoir J-M 1998 Functional relationships between steroid receptors and immunophilins. In: Current topics in steroid research, vol 1. Trivandrum, India: Research Trends; 59-71
4. Parker MG 1998 Transcriptional activation by oestrogen receptors. Biochem Soc Symp 63:45-50
5. Robyr D, Wolffe AP, Wahli W 2000 Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol Endocrinol 14:329-347
6. Kouzarides T 1999 Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 9:40-48
7. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-759
8. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner P, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
9. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Chang C, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM 1999 Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β. Proc Natl Acad Sci USA 96:3999-4004
10. Norris JD, Paige LA, Christensen DJ, Chang C-Y, Huacani MR, Fan D, Hamilto PT, Fowlkes DM, McDonnell DP 1999 Peptide antagonists of the human estrogen receptor. Science 285:744-746
11. Lannigan DA 2003 Estrogen receptor phosphorylation. Steroids 68:1-9
12. Scholl S, Lippman ME 1984 The estrogen receptor in MCF-7 cells: evidence from dense amino acid labeling for rapid turnover and a dimeric model of activated nuclear receptor. Endocrinology 115:1295-1301
13. Eckert RL, Mullick A, Rorke EA, Katzenellenbogen BS 1984 Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology 114:629-637
14. Nirmala PB, Thampan RV 1995 Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. Biochem Biophys Res Commun 213:24-31
15. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW 1999 Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 96:1858-1862
16. Alarid ET, Bakopoulos NS, Solodin N 1999 Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down regulation. Mol Endocrinol 13:1522-1534
17. El Khissiin A, Leclercq G 1999 Implication of proteasome in estrogen receptor degradation. FEBS Lett 448:160-166
18. Lonard DM, Nawaz Z, Smith CL, O'Malley BW 2000 The 26S proteasome is required for estrogen receptor α and coactivator turnover and for efficient ER-α transactivation. Mol Cell 5:939-948
19. Wijayaratne AL, McDonnell DP 2001 The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differently by agonists, antagonists and selective estrogen receptor modulators. J Biol Chem 276:35684-35692
20. De Friend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C, Baum M, Walton P, Sutcliffe F, Wakeling AW 1994 Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54:408-414
21. Dauvois S, Daniellian PS, White R, Parker MG 1992 Antiestrogen ICI164, 384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89:4037-4041
22. Stenoien DL, Mancini MG, Patel K, Allegretto EA, Smith CL, Mancini MA 2000 Subnuclear trafficking of estrogen receptor-α and steroid receptor coactivator-1. Mol Endocrinol 14:518-534
23. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494
24. Bunone G, Briand PA, Miksicek RJ, Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15:2174-2183
25. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H 2001 Phosphatidylinositol-3-kinase/AKT-mediated activation of estradi receptor α. A new model for anti-estrogen resistance. J Biol Chem 276:9817-9824
26. Power RF, Mani SK, Codina J, Conneely OM, O'Malley BW 1991 Dopaminergic and ligand-independent activation of steroid hormone receptor. Science 254:1636-1639
27. Aronica SM, Kraus WL, Katzenellenbogen BS 1994 Estrogen action via the cAmp signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA 91:8517-8521
28. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446
29. Oh A, Lorant LA, Holloway JM, Miller DL, Kern FG, El-Ashri D 2001 Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Mol Endocrinol 15:1344-1359
30. Lange CA, Shen T, Horwitz KB 2000 Phosphorylation of human progesterone receptors at serine-194 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 97:1032-1037
31. Van de Velde P, Nique F, Bouchoux F, Bremaud J, Hameau MC, Lucas D, Moratille C, Viet S, Philibert D, Teutsch, G 1994 RU 58,668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J Steroid Biochem Mol Biol 48:187-196
32. Coopman P, Garcia M, Brünner N, Derocq D, Clarke R, Rochefort H 1994 Anti-proliferative and anti-estrogenic effects of ICI164384 and ICI 182780 in 4-OH-tamoxifen-resistant breast cancer cells. Int J Cancer 56:295-300
33. Van de Velde P, Nique F, Bremaud J, Hameau MC, Philibert D, Teutsch G 1995 Exploration of the therapeutic potential of the antiestrogen RU 58668 in breast cancer treatment. Ann NY Acad Sci 761:164-175
34. Van de Velde P, Nique F, Planchon P, Prevost G, Bremaud, J, Hameau, MC, Magnien V, Philibert D, Teutsch G 1996 RU 58668: further in vitro and in vivo pharmacological data related to its antitumoral activity. J Steroid Biochem Mol Biol 59:449-457
35. Saceda M, Lippman ME, Chambon P, Lindsey RL, Ponglikitmongkol M, Puente M, Martin MB 1988 Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol 2:1157-1162
36. Read LD, Greene GL, Katzenellenbogen BS 1989 Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. Mol Endocrinol 3:295-304
37. Meng L, Mohan R, Kwok BHB, Elofsson M, Sin N, Crews CM 1999 Epoxomycin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc Natl Acad Sci USA 96:10403-10408
38. Metzger DA, Korach KS 1990 Cell-free interaction of the estrogen receptor with mouse uterine nuclear matrix; evidence of saturability, specificity, and resistance to KCl extraction. Endocrinology 126:2190-2195
39. Htun H, Holth LT, Walker D, Davie JR, Hager GL 1999 Direct visualisation of the human estrogen receptor α reveals a role for ligand in the nuclear distribution of the receptor. Mol Biol Cell 10:471-486
40. Stenoien DL, Patel K, Mancini MG, Dutertre M, Smith CL, O'Malley BW, Mancini MA 2000 FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependant. Nat Cell Biol 3:15-23
41. Müller V, Jensen EV, Knabbe C 1998 Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Cancer Res 58:263-267
42. 2 activation is via the MKP-1 down-regulation and ERK activation. Cell Signal 12:457-461
43. Kim Y-H, Choi M-R, Song D-K, Huh S-O, Jang C-G, Suh H-W 2000 Regulation of c-fos gene expression by lipopolysaccharide and cycloheximide in C6 rat glioma cells. Brain Res 872:227-230
44. Carosti S, Galera JL, Matarese F, Imai M, Caporali S, Cancemi M, Altucci L, Cicatiello L, Teti D, Bresciani F, Weisz A 2001 Estrogens do not modify MAP kinase-dependent nuclear signalling during stimulation of early G(1) progression in human breast cancer cells. Cancer Res 61:6360-6366
45. Lobenhofer EK, Huper G, Iglehart JD, Marks JR 2000 Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Diff 11:99-110
46. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Aurichio F 1996 Tyrosine kinase/p21 ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15:1292-1300
47. Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP 1999 Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci USA 96:4686-4691
48. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB 1985 Inhibition of protein kinase C by tamoxifen. Cancer Res 45:2462-2465
49. Bignon E, Pons M, Dore JC, Gilbert J, Ojasoo T, Miquel JF, Raynaud JP, Crastes de Paulet A 1991 Influence of di-and tri-phenylethylene estrogen/antiestrogen structure on the mechanisms of protein kinase C inhibition and activation as revealed by a multivariate analysis. Biochem Pharmacol 42:1373-1383
50. Nishio H, Ikegami Y, Segawa, T, Nakata Y 1994 Stimulation of calcium sequestration by mezerein, a protein kinase C activator, in saponized rabbit platelets. Gen Pharmacol 25:413-416
51. Clarke R, Leonessa F, Welch J, Skaar TD 2001 Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25-71
52. Devin-Leclerc J, Meng X, Delahaye F, Leclerc P, Baulieu EE, Catelli MG 1998 Interaction and dissociation by ligands of estrogen receptor and Hsp90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. Mol Endocrinol 12:842-854
53. Nawaz Z, Lonard D, Smith CL, Lev-Lheman E, Tsai SY, Tsai M-J, O'Malley BW 1999 The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 19:1182-1189
54. Lee JW, Ryan F, Swaffield JC, Johnston SA, Moore DD 1995 Interaction of thyroid hormone receptor with a conserved transcriptional mediator. Nature 374:91-94
55. Rubin DM, Coux O, Wefes I, Hengartner C, Young RA, Goldberg AL, Finley D 1996 Identification of the Gal4 suppresseur Sug1 as a subunit of the yeast 26-S proteasome. Nature 379:655-657
56. Eggert M, Michel J, Schneider S, Bornfleth H, Beniahmad A, Fackelmayer F, Renkawitz R 1997 The glucocorticoid receptor is associated with the RNA-binding nuclear matrix protein hnRNP U. J Biol Chem 272:28471-28478
57. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson L, Höfeld J, Patterson C 2000 The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 3:93-96
58. Murata S, Minami Y, Minami M, Chiba T, Tanaka K 2001 CHIP is a chaperone-dependent E3 ligase that ubiquitinates unfolded protein. EMBO Rep 21:1-6
59. Renz A, Fackelmayer FO 1996 Purification and molecular cloning of the scaffold attachment factor B (SAF-B), a novel human nuclear protein that specifically binds to S/MAR-DNA. Nucleic Acids Res 24:843-849
60. Oesterreich S, Zhang Q, Hopp T, Fuqua SAW, Michaelis M, Zhao HH, Davie J, Osborne CK, Lee AV 2000 Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol 14: 369-381
61. Seeger M, Kraft R, Ferrell K, Bech-Otshir D, Dumdey R, Schade R, Gordon C, Naumann M, Dubiel W 1998 A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J 12:469-478
62. Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J Biol Chem 277:2302-2310
63. Fan M, Bigsby R, Nephew K P 2003 The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-α and essential for the anti-proliferative activity of ICI 182,780 in ERα-positive breast cancer cells. Mol Endocrinol 17:356-365
64. Giamarchi C, Chailleux C, Calligé M, Rochaix P, Trouche D, Richard-Foy H 2002 Two antiestrogens affect differently chromatin remodeling of trefoil factor 1 (pS2) gene and the fate of estrogen receptor in MCF-7. Biochem Biophys Acta 1578:12-20
65. Marquardt B, Fritz D, Stabel S 1994 Signalling from TPA to MAP kinase requires protein kinase C, raf and MEK: reconstitution of the signaling pathway in vitro. Oncogene 9:3213-3218
66. Brändlin I, Hübner S, Eiseler T, Martinez-Moya M, Horshineck A, Hausser A, Link G, Rupp S, Storz P, Pfizenmaier K, Johannes F-J 2002 Protein kinase C (PKC)η-mediated PKCμ activation modulates ERK and JNK signal pathways. J Biol Chem 277:6490-6496
67. Lamb J, Ladha MH, McMahon C, Sutherland RL, Ewen ME 2000 Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol 20:8667-8675
68. Deroo BJ, Archer TK 2002 Proteasome inhibitors reduce luciferase and β galactosidase activity in tissue culture cells. J Biol Chem 227:20120-20123
69. Hershko A, Ciekhanover A 1998 The ubiquitin system. Annu Rev Biochem 67:425-479
70. Gagne D, Balaguer P, Demirpence E, Chabret C, Trousse F, Nicolas JC, Pons M 1994 Stable luciferase transfected cells for studying steroid receptor biological activity. J Biolumin Chemilumin 9:201-209
71. Balaguer P, Francois F, Comunale F, Fenet H, Boussioux AM, Pons M, Nicolas JC, Casellas C 1999 Reporter cell lines to study the estrogenic effects of xenoestrogens. Sci Total Environ 15:47-56